|
1.
|
World Health Organization (WHO) Hepatitis
C. 2006, Available at: http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html#disease%20burdenuri.
|
|
2.
|
Chander G, Sulkowski MS, Jenckes MW,
Torbenson MS, Herlong HF, Bass EB and Gebo KA: Treatment of chronic
hepatitis C: a systematic review. Hepatology. 36:S135–S144. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Kato N, Hijikata M, Ootsuyama Y, Nakagawa
M, Ohkoshi S and Sugimura T: Molecular cloning of the human
hepatitis C virus genome from Japanese patients with non-A, non-B
hepatitis. Proc Natl Acad Sci USA. 87:9524–9528. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Blatt LM, Mutchnick MG, Tong MJ, et al:
Assessment of hepatitis C virus RNA and genotype from 6807 patients
with chronic hepatitis C in the United States. J Viral Hepat.
7:196–202. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Yoshida H, Shiratori Y, Moriyama M, et al:
Interferon therapy reduces the risk for hepatocellular carcinoma:
national surveillance program of cirrhotic and noncirrhotic
patients with chronic hepatitis C in Japan. IHIT Study Group.
Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann
Intern Med. 131:174–181. 1999. View Article : Google Scholar
|
|
6.
|
Houghton M and Abrignani S: Prospects for
a vaccine against the hepatitis C virus. Nature. 436:961–966. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Strickland GT, EI-Kamary SS, Klenerman P
and Nicosia A: Hepatitis C vaccine: supply and demand. Lancet
Infect Dis. 8:379–386. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Bowen DG and Walker CM: Mutational escape
from CD8+ T cell immunity: HCV evolution, from chimpanzees to man.
J Exp Med. 201:1709–1714. 2005.
|
|
9.
|
Schlaphoff V, Klade CS, Jilma B, et al:
Functional and phenotypic characterization of
peptide-vaccine-induced HCV-specific CD8+ T cells in healthy
individuals and chronic hepatitis C patients. Vaccine.
25:6793–6806. 2007.PubMed/NCBI
|
|
10.
|
Klade CS, Wedemeyer H, Berg T, et al:
Therapeutic vaccination of chronic hepatitis C nonresponder
patients with the peptide vaccine IC41. Gastroenterology.
134:1385–1395. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Yutani S, Yamada A, Yoshida K, et al:
Phase I clinical study of a personalized peptide vaccination for
patients infected with hepatitis C virus (HCV) 1b who failed to
respond to interferon-based therapy. Vaccine. 25:7429–7435. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Yutani S, Komatsu N, Shichijo S, et al:
Phase I clinical study of a peptide vaccination for hepatitis C
virus-infected patients with different HLA-class I-A alleles.
Cancer Science. 100:1935–1942. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Leroux-Roels G, Batens AH, Desombere I, et
al: Immunogenicity and tolerability of intradermal administration
of an HCV E1-based vaccine candidate in healthy volunteers and
patients with resolved or ongoing chronic HCV infection. Hum
Vaccin. 1:61–65. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Niu Y, Terasaki Y, Komatsu N, et al:
Identification of peptides applicable as vaccines for
HLA-A26-positive cancer patients. Cancer Science. 100:2167–2174.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Cerny A, McHutchison JG, Pasquinelli C, et
al: Cytotoxic T lymphocyte response to hepatitis C virus-derived
peptides containing the HLA A2.1 binding motif. J Clin Invest.
95:521–530. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Kiyosawa K, Umemura T, Ichijo T, et al:
Hepatocellular carcinoma: recent trends in Japan. Gastroenterology.
127:S17–S26. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Taura K, Ikai I, Hatano E, et al:
Influence of coexisting cirrhosis on outcomes after partial hepatic
resection for hepatocellular carcinoma fulfilling the Milan
criteria: an analysis of 293 patients. Surgery. 142:685–694. 2007.
View Article : Google Scholar
|
|
18.
|
Shiratori Y, Shiina S, Teratani T, et al:
Interferon therapy after tumor ablation improves prognosis in
patients with hepatocellular carcinoma associated with hepatitis C
virus. Ann Intern Med. 138:299–306. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Kubo M, Sakaguchi Y, Chung H, et al:
Long-term interferon maintenance therapy improves survival in
patients with HCV-related hepatocellular carcinoma after curative
radiofrequency ablation. A matched case-control study. Oncology.
72:132–138. 2007. View Article : Google Scholar
|
|
20.
|
Kim JH, Han KH, Lee KS, et al: Efficacy
and long term follow up of combination therapy with interferon
alpha and ribavirin for chronic hepatitis C in Korea. Yonsei
Medical Journal. 47:793–798. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Arase Y, Ikeda K, Suzuki F, et al: Long
term outcome after interferon therapy in elderly patients with
chronic hepatitis C. Intervirology. 50:16–23. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Ikeda K, Saitoh S, Arase Y, et al: Effect
of interferon therapy on hepatocellular carcinogenesis in patients
with chronic hepatitis type C: a long-term observation study of
1,643 patients using statistical bias correction with proportional
hazard analysis. Hepatology. 29:1124–1130. 1999. View Article : Google Scholar
|
|
23.
|
Toyoda H, Kumada T, Tokuda A, et al:
Long-term follow-up of sustained responders to interferon therapy
in patients with chronic hepatitis C. J Viral Hepatitis. 7:414–419.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Okanoue T, Itoh Y, Minami M, et al:
Interferon therapy lowers the rate of progression to hepatocellular
carcinoma in chronic hepatitis C but not significantly in an
advanced stage: a retrospective study in 1148 patients. J Hepatol.
30:643–649. 1999. View Article : Google Scholar
|
|
25.
|
Bertoketti A, Bertoletti A, D’Elios MM, et
al: Different cytokine profiles of intrahepatic T cells in chronic
hepatitis B and hepatitis C virus infections. Gastroenterology.
112:193–199. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
McGuinness PH, Painter D, Davies S and
McCaughan GW: Increases in intrahepatic CD68 positive cells, MAC387
positive cells and proinflammatory cytokines (particularly
interleukin 18) in chronic hepatitis C infection. Gut. 46:260–269.
2000. View Article : Google Scholar
|
|
27.
|
Nelson DR, Lauwers GY, Lau JY and Davis
GL: Interleukin 10 treatment reduces fibrosis in patients with
chronic hepatitis C: a pilot trial of interferon nonresponders.
Gastroenterology. 118:655–660. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Brière F, Servet-Delprat C, Bridon JM,
Saint-Remy JM and Banchereau J: Human interleukin 10 induces naive
surface immunoglobulin D+ (sIgD+) B cells to secrete IgG1 and IgG3.
J Exp Med. 179:757–762. 1994.PubMed/NCBI
|
|
29.
|
Defrance T, Vanbervliet B, Brière F, et
al: Interleukin 10 and transforming growth factor beta cooperate to
induce anti-CD40-activated naive human B cells to secrete
immunoglobulin A. J Exp Med. 175:671–682. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Rushbrook SM, Ward SM, Unitt E, et al:
Regulatory T cells suppress in vitro proliferation of
virus-specific CD8+ T cells during persistent hepatitis C virus
infection. J Virol. 79:7852–7859. 2005.
|
